
SUMMARY


In one aspect, there is provided a radiopharmaceutical of the chemical formula ^{99m}Tc-EDDA/HYNIC-iFAP (^{99m}Tc-HYNIC-iFAP), comprising the structure:




.

In another aspect, there is provided a radiopharmaceutical composition, characterized in that it comprises the radiopharmaceutical as defined herein.

In another aspect, there is provided a precursor ligand of radiopharmaceuticals comprising the structure:



R=H (1)

R= DOTA 

(2)